CRB-913 was safe and well-tolerated across all doses studiedDaily neuropsychiatric assessments using CSSRS, PHQ-9, and GAD-7 were negative for ...

CRB-913 is an oral small-molecule inverse agonist targeting the CB1 receptor, a known pathway for weight loss. ・The study ...

Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP) climbed 5% after the company released promising early-stage safety data ...

To register for the webcast, click here . A replay will be available on the Corbus website.

NORWOOD, Mass., June 30, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical-stage company focused on oncology and obesity, today announced the initiation of the ...

PALO ALTO, Calif.--(BUSINESS WIRE)--OrsoBio, Inc., a clinical-stage biopharmaceutical company developing treatments for severe metabolic disorders, today announced its acquisition of assets relating ...

Recent advances in immunology have underscored the pivotal role of the transcription factor RORγt in orchestrating the differentiation of Th17 cells and the consequent production of proinflammatory ...

Researchers from Flare Therapeutics Inc. presented the discovery of a first-in-class covalent peroxisome proliferator-activated receptor γ (PPARγ) inverse agonist, FX-909, being developed for the ...

Although class A G protein–coupled receptors (GPCRs) can function as monomers, many of them form dimers and oligomers, but the mechanisms and functional relevance of such oligomerization is ill ...

CRB-913 is a member of a new class of peripherally restricted CB1 inverse agonists designed to have reduced brain penetration. Pre-clinical models have shown CRB-913 to be 15-fold less brain penetrant ...